ADC · 위암

16개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved16 programs
ADCCurated CoreFDADaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 240Status Approved
ADCCurated CoreFDARemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 159Status Active
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 134Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab)

HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 91Status Recruiting
ADCCurated CorestaleSuzhou Suncadia Biopharmaceutic…rezetecanPhase 3

SHR-A1811 (SHR-A1811)

Gastric Cancer; HER2 + Gastric Cancer · HER2

#HER2#ADC#Phase3#BioJungboMoa-pick#Popular+5
Trials 62Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCGovitecan in gynecologic ma…Phase 2

sac-TMT (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (sac-TMT))

Gastroesophageal Junction; Gastroesophageal Adenocarcinoma · Gastroesophageal Junction

#GastroesophagealJunction#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 62Status Recruiting
ADCStandard DatabasestaleDaiichi SankyoDM1) and trastuzumab deruxt…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzmab deruxtecan)

Gastric Cancer; Gastroesophageal Junction (GEJ) Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 56Status Recruiting
ADCStandard DatabasestaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 10Status Active
ADCLimited DatastaleAstraZenecaPhase 3

Sonesitatug vedotin (Sonesitatug vedotin)

Stomach Neoplasms · Gastric Cancer

#GastricCancer#ADC#Phase3#antibody-drug-conjugate#StomachNeoplasms+2
Trials 6Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Gastric Cancer · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#GastricCancer+1
Trials 2Status Active
ADCLimited DatastaleWest China Second University Ho…Phase 2

MRG003 (Becotatug Vedotin, Becotatug Vedotin (MRG003))

Gastric Cancer; Gastroesophageal Junction (GEJ) Adenocarcinoma · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#GastroesophagealJunctionGEJAdeno+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveGastricCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting